Search

Your search keyword '"Halfdan Sorbye"' showing total 156 results

Search Constraints

Start Over You searched for: "Halfdan Sorbye" Remove constraint "Halfdan Sorbye" Language undetermined Remove constraint Language: undetermined
156 results on '"Halfdan Sorbye"'

Search Results

1. Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

2. Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer

4. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas

5. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms

7. Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma

8. Abstract 3279: Systemic immune response invoked by short-course oxaliplatin-based chemotherapy (FLOX) for efficacy of sequential immune checkpoint blockade (ICB; nivolumab) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)

9. Clinicopathological factors associated with tumour‐specific mutation detection in plasma of patients with <scp> RAS </scp> ‐mutated or <scp> BRAF </scp> ‐mutated metastatic colorectal cancer

10. Volumetric parameters from [ <scp> 18 F </scp> ] <scp>FDG PET</scp> / <scp>CT</scp> predicts survival in patients with high‐grade gastroenteropancreatic neuroendocrine neoplasms

11. Volumetric parameters from [

12. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

13. Author response for 'Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumours and differentiation from small intestinal neuroendocrine tumours'

14. Author response for 'ENETS consensus guidance for synoptic reporting of molecular imaging studies'

15. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach

16. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer

17. Surgery of the primary tumour in 201 patients with high‐grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine‐non‐neuroendocrine neoplasms

18. Abstract 522: Immunogenic chemotherapy and immune checkpoint inhibition (ICI) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Biomarkers indicative of durable treatment response

20. SO-13 KRAS-G12C mutations in a Nordic cohort of 1441 metastatic colorectal cancer patients

21. Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours

22. Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors

23. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms

24. Abstracts

26. SO-15 Quality of life and physical functioning in older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study

27. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases

28. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study

29. 485P Link between PODXL and the EGFR axis in metastatic colorectal cancer and in vitro: Implications for improved treatment stratification

30. CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better

32. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors

34. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study

35. Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study

36. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review

37. Impact of <scp> KRAS </scp> , <scp> BRAF </scp> , <scp> PIK3CA </scp> , <scp> TP5 3 </scp> status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases

38. SO-22 Atypical non-V600E BRAF (aBRAF) mutations as a prognostic and predictive factor in real-life metastatic colorectal cancer patients from the Nordic countries

39. SO-35 Tumor infiltrating CD3 lymphocytes and CD68 macrophages are associated with long-time survival in metastatic colorectal cancer patients treated with chemotherapy

40. O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors

41. Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors

42. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond

43. Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver

44. Review on adjuvant chemotherapy for rectal cancer – why do treatment guidelines differ so much?

45. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab

46. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome

47. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases

48. A

49. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status

50. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy

Catalog

Books, media, physical & digital resources